Our 21st Annual Superbugs & Superdrugs Conference
will take place on 18th - 19th March 2019
Inspiring the global commitment required to tackle multidrug-resistance among bacteria populations, as the global threat of antimicrobial resistance continues to grow.
This year's event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.
Join us to learn about various strategies in place to support antimicrobial resistance research & development, evaluate the latest scientific advancements for tackling antimicrobial resistance and consider potential novel candidates and alternatives to anti-microbials.
The event will also focus on the strategies pharmaceutical companies use to assist the development of new therapeutics & drugs, how to obtain funding for new projects and address why there is a current lack of incentives for researchers working in antimicrobial resistance research and development.
Benefits of Attending
By attending our 21st annual Superbugs & Superdrugs
event, you will benefit from the knowledge delivered through range of thought-provoking presentations, by experts at the forefront of the field; receiving the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry - from research to commercial providers and regulatory bodies.
- Analyse the current status of antimicrobial resistance with industry-led insight into current strategies to tackle AMR
- Hear about novel immunotherapeutics to target Gram-negative bacterial infections
- Learn about strategies to combat β-lactamases
- Evaluate the development of precision antibiotics: agents designed to meet the demands of stewardship
- Explore the role of plasmids in the evolution of antimicrobial resistance
Who should attend
- Research and Development Directors
- Chief Scientific Officers
- Chief Medical Officers
- Heads of Global Antimicrobial Stewardship
- Pharmaceutical Research & Development/ Drug Discovery Scientists
Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday 20th March 2019Workshop A: Understanding the complexity of the microbiome and how to navigate it
Workshop Leader: Mahmoud Ghannoum, Director of Center for Medical Mycology, Case Western Reserve University
08.30 - 12.30 Workshop B: Understanding PK/PD in antimicrobial research
Workshop Leader: William Hope, Professor of Therapeutics and Infectious Diseases, University of Liverpool
13.30 - 17.00
- Anthony Coates, Chief Scientific Officer, St George's, University of London
- Carley Smith, Practitioner, Fairy Gut Mother
- Chandrabali Ghose, CEO, Bioharmony Therapeutics
- Chris Pickford, Head of Drug Discovery, Centauri Therapeutics
- Christopher Schofield, Head of Organic Chemistry, Oxford University
- David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd
- David Roblin, President of R&D, Chief Operating Officer and Chief Medical Officer, Summit Theraputics
- Eirikur Steingrimsson, Co-founder, Akthelia Pharmaceuticals
- Fiona Rudkin, Principal Investigator/CEO, MycoBiologics at University of Aberdeen
- John Rex, Chief Medical Officer , F2G Ltd
- Kazunori Maebashi, Senior Project Manager, Meiji Seika Pharma Co. Ltd.
- Laura Piddock, Professor of Microbiology, University of Birmingham
- Lloyd Czaplewski, Director, Chemical Biology Ventures
- Mair Powell, Senior Medical Officer, HPRA
- Michael Koehler, Senior Scientist, Genentech
- Peter Beyer, Senior Advisor , WHO
- Richard Bax, Senior Partner, TranScrip Partners
- Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
- Timothy Jinks, Senior Business Analyst, Wellcome Trust
- William Hope, Professor of Therapeutics and Infectious Diseases, University Of Liverpool
VenueHoliday Inn Kensington Forum
97 Cromwell Road
London, United Kingdom